IRIS
GIAMPIERI, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.027
AS - Asia 3.692
EU - Europa 3.618
SA - Sud America 921
Continente sconosciuto - Info sul continente non disponibili 288
AF - Africa 260
OC - Oceania 4
Totale 17.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.860
SG - Singapore 1.232
BR - Brasile 735
VN - Vietnam 722
CN - Cina 680
IT - Italia 679
RU - Federazione Russa 611
UA - Ucraina 432
DE - Germania 327
SE - Svezia 324
HK - Hong Kong 314
IE - Irlanda 309
FR - Francia 218
TR - Turchia 217
FI - Finlandia 195
GB - Regno Unito 164
DK - Danimarca 152
IN - India 115
CI - Costa d'Avorio 99
BD - Bangladesh 86
KR - Corea 84
CA - Canada 82
AR - Argentina 70
MA - Marocco 57
MX - Messico 54
ZA - Sudafrica 49
JP - Giappone 46
NL - Olanda 45
IQ - Iraq 37
PL - Polonia 37
ES - Italia 32
CO - Colombia 31
EC - Ecuador 28
ID - Indonesia 27
VE - Venezuela 20
MY - Malesia 19
BE - Belgio 18
PK - Pakistan 14
UZ - Uzbekistan 14
CL - Cile 13
AT - Austria 12
AZ - Azerbaigian 12
TH - Thailandia 11
TN - Tunisia 11
DZ - Algeria 10
SK - Slovacchia (Repubblica Slovacca) 10
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
KE - Kenya 8
PH - Filippine 8
PY - Paraguay 8
EG - Egitto 7
LT - Lituania 7
PE - Perù 7
RS - Serbia 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
CR - Costa Rica 6
UY - Uruguay 6
ET - Etiopia 5
EU - Europa 5
HN - Honduras 5
PA - Panama 5
PT - Portogallo 5
RO - Romania 5
AU - Australia 4
BH - Bahrain 4
IL - Israele 4
JM - Giamaica 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GT - Guatemala 2
HR - Croazia 2
LB - Libano 2
LY - Libia 2
MD - Moldavia 2
MK - Macedonia 2
NG - Nigeria 2
NP - Nepal 2
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
GD - Grenada 1
GE - Georgia 1
IM - Isola di Man 1
IR - Iran 1
LK - Sri Lanka 1
LV - Lettonia 1
Totale 17.516
Salva come PNG Salva come JPEG
Città #
Ashburn 1.697
Singapore 802
Chandler 624
Fairfield 496
San Jose 482
Jacksonville 469
Des Moines 352
Dallas 336
Dublin 304
Hong Kong 301
Council Bluffs 295
Boardman 290
New York 264
Wilmington 261
Ho Chi Minh City 230
Woodbridge 227
Beijing 195
Seattle 195
Houston 188
Hanoi 181
The Dalles 164
Los Angeles 161
Ann Arbor 160
Cambridge 148
Lauterbourg 113
Lawrence 113
Princeton 113
Centro 105
Moscow 104
San Mateo 104
Abidjan 98
Munich 90
Turku 70
Turin 67
Buffalo 59
São Paulo 58
Chicago 57
Milan 56
Hefei 54
Santa Clara 53
Orem 50
Helsinki 48
San Diego 48
London 46
Ancona 36
Tokyo 36
Chennai 35
Montreal 33
Washington 33
Johannesburg 32
Warsaw 31
Atlanta 28
Denver 28
Haiphong 28
Da Nang 27
Pune 25
Amsterdam 24
Columbus 24
Frankfurt am Main 23
Brooklyn 22
Rio de Janeiro 22
Stockholm 22
Rome 21
Toronto 21
Porto Alegre 20
Miano 19
Guangzhou 18
Mexico City 18
Manchester 17
Wuhan 17
Brussels 16
Poplar 16
Shanghai 16
Brasília 14
Hải Dương 14
New Delhi 14
Paris 14
Belo Horizonte 13
Campinas 13
Nuremberg 13
Phoenix 13
Baghdad 12
Baku 12
Cagliari 12
Curitiba 12
Norwalk 12
Tashkent 12
Thái Nguyên 12
Boston 11
Guayaquil 11
Izmir 11
Miami 11
Salvador 11
Biên Hòa 10
Can Tho 10
Elk Grove Village 10
Salt Lake City 10
Bangkok 9
Bến Tre 9
Fortaleza 9
Totale 11.350
Salva come PNG Salva come JPEG
Nome #
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 255
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 229
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 223
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy 213
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 209
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 204
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 200
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 198
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 197
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 196
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 195
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 195
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 195
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 193
Optimal management of resected gastric cancer 189
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 184
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 184
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 184
5-Fluorouracil pharmacogenomics: still rocking after all these years? 175
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 175
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 170
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 170
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 169
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 168
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab 165
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 164
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 164
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 163
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 160
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 158
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 158
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 156
Adjuvant treatment after surgical resection 156
BRAF-mutant colorectal cancer, a different breed evolving 154
Benefits and limitations of a multidisciplinary approach in cancer patient management 154
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 151
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 150
Panitumumab for the treatment of metastatic colorectal cancer: A review 150
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 149
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 149
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 148
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 147
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 147
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 146
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 146
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 145
Trattamento del carcinoma del pancreas. Attualità e prospettive 145
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 144
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 143
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 143
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 143
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. 142
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 142
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 141
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 140
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 138
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 138
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase 138
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 137
Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study 137
Novel perspectives for the treatment of gastric cancer: From a global approach to a personalized strategy 137
BRCA mutations and gastrointestinal cancers: When to expect the unexpected? 136
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 135
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 135
New Insights into Hormonal Therapies in Uterine Sarcomas 135
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 134
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study 134
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 133
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 133
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 132
Screening of psychological distress in oncology and hematology department at Ospedali Riuniti Ancona 131
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 130
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 129
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 128
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 128
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 126
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 126
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 125
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 125
Selecting the best treatment for an individual patient. 121
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 120
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 119
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 119
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 118
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 117
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 116
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? 116
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab 116
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. 114
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 114
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 112
Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: biological and clinical implications 112
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 112
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 111
Gastric cancer: Therapeutic choices in advanced disease 111
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. 110
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 108
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 107
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 106
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study 106
Totale 14.898
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.288
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.288
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022822 0 200 20 19 6 60 34 58 62 112 92 159
2022/20232.081 132 250 137 140 120 512 1 99 436 24 192 38
2023/20241.154 175 25 99 131 164 315 12 41 2 26 19 145
2024/20252.446 315 190 62 41 125 100 241 92 455 212 302 311
2025/20267.308 492 521 416 822 926 531 1.184 652 572 645 217 330
2026/2027542 285 257 0 0 0 0 0 0 0 0 0 0
Totale 17.810